Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature

Presently, the use of convalescent plasma and hyperimmunoglobulin obtained from individuals who have recovered from coronavirus disease 2019 (COVID-19) has proved to potentially provide passive antibody-based immunity, thereby leading to several clinical trials to develop an immune-based COVID-19 tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Sunha, Hwang, Soyoon, Kwon, Kitae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473256/
https://www.ncbi.nlm.nih.gov/pubmed/34578407
http://dx.doi.org/10.3390/v13091826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473256/
https://www.ncbi.nlm.nih.gov/pubmed/34578407
http://dx.doi.org/10.3390/v13091826

Ejemplares similares